Skip to Content

New Drug Approvals Archive - February 2009

February 2009

ATryn (Antithrombin (Recombinant))

Date of Approval: February 6, 2009
Company: GTC Biotherapeutics, Inc.
Treatment for: Antithrombin III Deficiency

ATryn (Antithrombin (Recombinant)) is a recombinant form of human antithrombin for the prevention of peri-operative and peri-partum thromboembolic events in hereditary antithrombin deficient patients.

Read more: ATryn (Antithrombin (Recombinant)) FDA Approval History

Uloric (febuxostat) Tablets

Date of Approval: February 13, 2009
Company: Takeda Pharmaceutical Company Limited
Treatment for: Gout

Uloric (febuxostat) is a xanthine oxidase inhibitor indicated for the chronic management of hyperuricemia in patients with gout.

Read more: Uloric (febuxostat) FDA Approval History

New Drug Approvals Archive